CLINICAL TRIALS PROFILE FOR OCREVUS

« Back to Dashboard

All Clinical Trials for OCREVUS

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01466114 ↗	Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition	Recruiting	Synthetic Biologics (formerly Adeona Pharmaceuticals)	Phase 2	2011-10-01	Approximately 50% of people diagnosed with Multiple Sclerosis (MS) will develop problems with cognition. Currently, there are no FDA-approved treatments targeting cognitive function in Multiple Sclerosis. This trial will ascertain whether treatment with an estrogen pill, used in combination with standard MS anti-inflammatory drugs, can improve cognitive testing as compared to treatment with a placebo pill in combination with standard anti-inflammatory drugs in women with MS.
NCT01466114 ↗	Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition	Recruiting	University of California, Los Angeles	Phase 2	2011-10-01	Approximately 50% of people diagnosed with Multiple Sclerosis (MS) will develop problems with cognition. Currently, there are no FDA-approved treatments targeting cognitive function in Multiple Sclerosis. This trial will ascertain whether treatment with an estrogen pill, used in combination with standard MS anti-inflammatory drugs, can improve cognitive testing as compared to treatment with a placebo pill in combination with standard anti-inflammatory drugs in women with MS.
NCT02980042 ↗	Safety of Switching From Rituximab to Ocrelizumab in MS Patients	Completed	University of Colorado, Denver	Phase 3	2017-01-01	This is a prospective between and within group observational study to determine differences in tolerability, immunogenicity and safety related outcomes for 100 multiple sclerosis (MS) patients who have been administered at least two infusions of rituximab, six months apart and are willing to be switched to ocrelizumab compared to a 100 patients who are continuing on rituximab as a comparison cohort from the clinic population treated as part of clinical care.

Clinical Trial Conditions for OCREVUS

Condition Name

Condition Name for OCREVUS
Intervention	Trials
Multiple Sclerosis	5
Relapsing Multiple Sclerosis	2
Relapsing Remitting Multiple Sclerosis	2

Condition MeSH

Condition MeSH for OCREVUS
Intervention	Trials
Multiple Sclerosis	14
Sclerosis	13
Multiple Sclerosis, Relapsing-Remitting	6

Clinical Trial Locations for OCREVUS

Trials by Country

Trials by Country for OCREVUS
Location	Trials
United States	91
Ukraine	23
Russian Federation	22
Italy	20
Brazil	17

Trials by US State

Trials by US State for OCREVUS
Location	Trials
California	7
Colorado	5
Texas	5
Michigan	4
Florida	4

Clinical Trial Progress for OCREVUS

Clinical Trial Phase

Clinical Trial Phase for OCREVUS
Clinical Trial Phase	Trials
PHASE3	1
Phase 4	7
Phase 3	6

Clinical Trial Status

Clinical Trial Status for OCREVUS
Clinical Trial Phase	Trials
Recruiting	10
Not yet recruiting	2
Active, not recruiting	2

Clinical Trial Sponsors for OCREVUS

Sponsor Name

Sponsor Name for OCREVUS
Sponsor	Trials
Hoffmann-La Roche	3
Genentech, Inc.	2
Johns Hopkins University	2

Sponsor Type

Sponsor Type for OCREVUS
Sponsor	Trials
Other	37
Industry	8
NIH	1